Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Alogliptin Benzoate (SYR 322) 是一种有效且特异性的 DPP-4 抑制剂 ,IC50值小于 10 nM,其选择性比 DPP-8/9 高 10,000 倍以上,可用于研究 2 型糖尿病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 196 | 现货 | ||
5 mg | ¥ 455 | 现货 | ||
10 mg | ¥ 597 | 现货 | ||
25 mg | ¥ 753 | 现货 | ||
50 mg | ¥ 997 | 现货 | ||
100 mg | ¥ 1,420 | 现货 | ||
200 mg | ¥ 2,090 | 现货 | ||
500 mg | ¥ 3,550 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 490 | 现货 |
产品描述 | Alogliptin Benzoate (SYR 322)(SYR 322), an effective and specific DPP-4 inhibitor (IC50<10 nM), exhibits greater than 10, 000-fold selectivity over DPP-8/9. Alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. |
靶点活性 | DPP4:<10 nM |
体外活性 | Alogliptin(SYR-322) is a potent inhibitor of DPP-4 and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9. Alogliptin is not an inhibitor of CYP-450 enzymes and does not block the hERG channel at concentrations up to 30 μM. [1] |
体内活性 | Alogliptin(SYR-322) produces dose-dependent improvements in glucose tolerance and increases plasma insulin levels in female Wistar fatty rats. [1] Acute administration of alogliptin results in a significant decrease in plasma DPP-4 activity, and increases plasma active GLP-1. Alogliptin improves glucose tolerance at a dose of 0.3 mg/kg and higher, with a dose-dependent increase in plasma IRI, suggesting that improved glucose tolerance results from the ability of alogliptin to enhance insulin secretion. [2] |
别名 | 苯甲酸阿格列汀, SYR 322, Alogliptin(SYR-322)benzoate |
分子量 | 461.51 |
分子式 | C25H27N5O4 |
CAS No. | 850649-62-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 63 mg/mL (136.5 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 2 mg/mL (4.33 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 2.1668 mL | 10.834 mL | 21.668 mL | 54.17 mL |
DMSO | 5 mM | 0.4334 mL | 2.1668 mL | 4.3336 mL | 10.834 mL |
10 mM | 0.2167 mL | 1.0834 mL | 2.1668 mL | 5.417 mL | |
20 mM | 0.1083 mL | 0.5417 mL | 1.0834 mL | 2.7085 mL | |
50 mM | 0.0433 mL | 0.2167 mL | 0.4334 mL | 1.0834 mL | |
100 mM | 0.0217 mL | 0.1083 mL | 0.2167 mL | 0.5417 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Alogliptin Benzoate 850649-62-6 Apoptosis Proteases/Proteasome Ubiquitination Ferroptosis Proteasome DPP-4 inhibit 苯甲酸阿格列汀 SYR-322 DPP Alogliptin diabetes Dipeptidyl Peptidase Inhibitor SYR 322 Alogliptin(SYR-322)benzoate SYR322 inhibitor